Literature DB >> 23173758

Aspiration pneumonia in patients treated with radiotherapy for head and neck cancer.

Hanna R Mortensen1, Kenneth Jensen, Cai Grau.   

Abstract

UNLABELLED: Aspiration and aspiration pneumonia has been reported with a high incidence in head and neck cancer populations treated with chemo-radiotherapy. The aim of this study was to investigate the incidence and mortality of aspiration pneumonia in an unselected series of head and neck cancer patients treated with curative radiotherapy with or without concurrent weekly cisplatin.
MATERIAL AND METHODS: A total of 324 consecutive patients treated with curative intended radiotherapy for head and neck cancer in a single Danish referral center in Aarhus from 2006 to 2008 were included and followed for a median of 4.3 years. Data on patient, tumor and treatment characteristics were obtained from the DAHANCA database. Data on hospital admissions were obtained from the National Patient Registry. Data from the National Registry of Causes of Death were obtained on all deaths and causes of death.
RESULTS: Severe dysphagia occurred in 32% of the 324 patients included. A total of 18 patients developed aspiration pneumonia, corresponding to an incidence rate of 29 (95% CI 17-46) per 1000 person-years and an incidence proportion of 5.3% (95% CI 3.1-8.3%) in the first year after radiotherapy; significant risk factors included tube feeding, clinical stage, severe dysphagia and incomplete response to treatment. Three of the 18 patients with aspiration pneumonia died from this complication.
CONCLUSION: Dysphagia-related aspiration and aspiration pneumonia are serious and potentially fatal treatment complications to accelerated radiotherapy, but occur less frequent than previously reported.

Entities:  

Mesh:

Year:  2012        PMID: 23173758     DOI: 10.3109/0284186X.2012.742205

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  16 in total

1.  Cross-Cultural Translation, Adaptation and Reliability of the Danish M. D. Andeson Dysphagia Inventory (MDADI) in Patients with Head and Neck Cancer.

Authors:  Sara Fredslund Hajdú; Christina Caroline Plaschke; Christoffer Johansen; Susanne Oksbjerg Dalton; Irene Wessel
Journal:  Dysphagia       Date:  2017-03-07       Impact factor: 3.438

2.  European white paper: oropharyngeal dysphagia in head and neck cancer.

Authors:  Laura W J Baijens; Margaret Walshe; Leena-Maija Aaltonen; Christoph Arens; Reinie Cordier; Patrick Cras; Lise Crevier-Buchman; Chris Curtis; Wojciech Golusinski; Roganie Govender; Jesper Grau Eriksen; Kevin Hansen; Kate Heathcote; Markus M Hess; Sefik Hosal; Jens Peter Klussmann; C René Leemans; Denise MacCarthy; Beatrice Manduchi; Jean-Paul Marie; Reza Nouraei; Claire Parkes; Christina Pflug; Walmari Pilz; Julie Regan; Nathalie Rommel; Antonio Schindler; Annemie M W J Schols; Renee Speyer; Giovanni Succo; Irene Wessel; Anna C H Willemsen; Taner Yilmaz; Pere Clavé
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-12-19       Impact factor: 2.503

3.  Predictive factors of head and neck squamous cell carcinoma patient tolerance to high-dose cisplatin in concurrent chemoradiotherapy.

Authors:  Kenji Nakano; Yasuyoshi Sato; Takashi Toshiyasu; Yukiko Sato; Lina Inagaki; Junichi Tomomatsu; Toru Sasaki; Wataru Shimbashi; Hirofumi Fukushima; Hiroyuki Yonekawa; Hiroki Mitani; Kazuyoshi Kawabata; Shunji Takahashi
Journal:  Mol Clin Oncol       Date:  2015-11-25

4.  Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer.

Authors:  Beibei Xu; Isabel J Boero; Lindsay Hwang; Quynh-Thu Le; Vitali Moiseenko; Parag R Sanghvi; Ezra E W Cohen; Loren K Mell; James D Murphy
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860

5.  Prophylactic Swallowing Exercises in Head and Neck Cancer Radiotherapy.

Authors:  H R Mortensen; K Jensen; K Aksglæde; K Lambertsen; E Eriksen; C Grau
Journal:  Dysphagia       Date:  2015-02-19       Impact factor: 3.438

6.  Impact of previous head and neck cancer on postoperative complications after surgical resection for lung cancer: a case-control study.

Authors:  Guillaume Briend; Benjamin Planquette; Alain Badia; Amandine Vial; Ollivier Laccourreye; Françoise Le Pimpec-Barthes; Guy Meyer; Olivier Sanchez
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

7.  Long term results of comparison of concurrent low-dose daily cisplatin versus the standard weekly cisplatin with six fractions per week radiotherapy in locally advanced head neck cancer.

Authors:  Pramod Kumar Gupta; Punita Lal; Ranjeet Bajpai; Anshu Goel; Rajan Yadav; Mranalini Verma; Shaleen Kumar
Journal:  South Asian J Cancer       Date:  2016 Apr-Jun

8.  DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.

Authors:  Imran Petkar; Keith Rooney; Justin W G Roe; Joanne M Patterson; David Bernstein; Justine M Tyler; Marie A Emson; James P Morden; Kathrin Mertens; Elizabeth Miles; Matthew Beasley; Tom Roques; Shreerang A Bhide; Kate L Newbold; Kevin J Harrington; Emma Hall; Christopher M Nutting
Journal:  BMC Cancer       Date:  2016-10-06       Impact factor: 4.430

9.  Risk factors for aspiration pneumonia after definitive chemoradiotherapy or bio-radiotherapy for locally advanced head and neck cancer: a monocentric case control study.

Authors:  Sadayuki Kawai; Tomoya Yokota; Yusuke Onozawa; Satoshi Hamauchi; Akira Fukutomi; Hirofumi Ogawa; Tsuyoshi Onoe; Tetsuro Onitsuka; Takashi Yurikusa; Akiko Todaka; Takahiro Tsushima; Yukio Yoshida; Yosuke Kito; Keita Mori; Hirofumi Yasui
Journal:  BMC Cancer       Date:  2017-01-17       Impact factor: 4.430

Review 10.  Respiratory and pulmonary complications in head and neck cancer patients: Evidence-based review for the COVID-19 era.

Authors:  Dustin A Silverman; Chen Lin; Akina Tamaki; Sidharth V Puram; Ricardo L Carrau; Nolan B Seim; Antoine Eskander; James W Rocco; Matthew O Old; Stephen Y Kang
Journal:  Head Neck       Date:  2020-04-30       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.